drugset / Trial / NCT01243190
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if ofatumumab can help to control CLL/SLL that has not yet been treated. The safety of this drug will also be studied.
Timeline
- Start
- 2011-03
- Primary completion
- 2023-03-28
- Completion
- 2023-03-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ofatumumab | Monoclonal antibody | 1000 mg | — |